# Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer

> **NCT03879811** · PHASE2 · WITHDRAWN · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** TMZ
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03879811
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-03-13
- **Primary completion:** 2021-03
- **Final completion:** 2021-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No accrual
- **Last updated:** 2025-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03879811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03879811, "Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03879811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*